Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) concerning whether a series of statements by Osmotica Pharmaceuticals plc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 27, 2019, the Company revealed preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change.

Following this news, NASDAQ: OSMT fell $2.74, or nearly 41%, to close at $4.00 on March 28, 2019.

Based in Bridgewater, New Jersey, Osmotica Pharmaceuticals plc develops, manufactures, and commercializes specialty products that target markets with underserved patient populations.

If you purchased shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) on or before March 27, 2019, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185